利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.021 秒)

    END MILL
    31.
    发明申请
    END MILL 有权
    末端铣刀

    公开(公告)号：US20130071192A1

    公开(公告)日：2013-03-21

    申请号：US13699831

    申请日：2011-05-27

    申请人： Masahiko Kuroda

    发明人： Masahiko Kuroda

    IPC分类号： B23C5/10

    CPC分类号： B23C5/10 ,  B23C5/1009 ,  B23C2210/086 ,  B23C2210/486 ,  B23C2210/64 ,  Y10T407/1948

    摘要： The invention provides an end mill having an improved chip discharging performance and capable of carrying out excellent cutting machining. The end mill includes an end cutting edge (2) provided on a front end of a tool body (1) which rotates around a central axis, a peripheral cutting edge (4) provided on an outer periphery of the tool body (1), a rake surface of the end cutting edge (2) and the peripheral cutting edge (4), and at least one recess (6), which locally breaks the continuity of the end cutting edge (2) is provided, wherein a wall section (8) which extends toward the rear of the outer peripheral side is provided at least in that area of the rake surface (3) which is closer to the outer peripheral side than the recess (6).

    摘要翻译： 本发明提供了具有改进的排屑性能并能够进行优异的切削加工的端铣刀。 端铣刀包括设置在围绕中心轴线旋转的工具主体（1）的前端的端部切削刃（2），设置在工具主体（1）的外周上的周边切削刃（4） 提供端部切削刃（2）和外围切削刃（4）的前刀面以及局部地破坏端部切削刃（2）的连续性的至少一个凹部（6），其中壁部 至少在前槽表面（3）的比凹部（6）更靠外周侧的区域中设置有朝向外周侧的后方延伸的区域（8）。

    METHOD FOR EVALUATING CANCER
    32.
    发明申请
    METHOD FOR EVALUATING CANCER 审中-公开
    癌症评估方法

    公开(公告)号：US20120115139A1

    公开(公告)日：2012-05-10

    申请号：US13265680

    申请日：2010-04-21

    申请人： Masahiko Kuroda ,  Akira Saito ,  Maki Sano

    发明人： Masahiko Kuroda ,  Akira Saito ,  Maki Sano

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.

    摘要翻译： 提供了一种使用新型癌症标志物评价受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。 使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评价中的新型癌症标志物。 检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。 根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。 作为检测癌症标记物的方法，优选使用例如相对于被固定化的样品的标记探针进行原位杂交法。

    MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT
    33.
    发明申请
    MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT 审中-公开
    乳腺癌诊断标记，测试方法和测试包

    公开(公告)号：US20110028332A1

    公开(公告)日：2011-02-03

    申请号：US12934948

    申请日：2009-03-27

    申请人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi

    发明人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi

    IPC分类号： C40B30/00 ,  C07H21/02 ,  C40B40/06

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.

    摘要翻译： 本发明的一个实施方案提供了可以检测在早期阶段（临床阶段0）不能通过触诊或乳房X线照相检查或乳腺癌检测到的乳腺癌发作的标志物，测试方法和测试试剂盒，其为 简单，可靠性高。 与本发明实施方案的乳腺癌相关的标志物的特征在于是在血清或血浆中发现的微RNA。 更具体地，标记物在乳腺癌发作后或在乳腺早期（临床阶段0期间或之后）期间或之后存在于血清或血浆中存在的至少一种微RNA，其显着降低水平 与乳腺癌发病前或乳腺癌早期（临床阶段0之前）癌症相比较。

    Oncogene, recombinant protein derived therefrom, and uses thereof
    35.
    发明授权
    Oncogene, recombinant protein derived therefrom, and uses thereof 有权

    公开(公告)号：US07432358B2

    公开(公告)日：2008-10-07

    申请号：US11449671

    申请日：2006-06-09

    申请人： Akira Saito ,  Masahiko Kuroda

    发明人： Akira Saito ,  Masahiko Kuroda

    IPC分类号： C07K16/00

    CPC分类号： C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.